Specific Changes: Incorporate recommendation and relevant citations for genetic risk assessment based on existing NCCN guidelines (Genetic/Familial High-Risk Assessment: Breast and Ovarian) into the Baseline Evaluation flowchart on page PROSD-2 and the discussion of Prostate Cancer Risk in Genetic Syndromes on page MS-11.

FDA Clearance: Not applicable.

Rationale: The NCCN Guideline for Genetic/Familial High-Risk Assessment: Breast and Ovarian provides specific criteria for genetic evaluation/referral and testing of individuals with a personal and/or family history of prostate cancer (pages BR/OV-1 and HBOC-1), as well as prostate screening recommendations for men identified with pathogenic mutations in the genes \textit{BRCA1} and \textit{BRCA2} as a result of genetic testing. Attention to these guidelines is a key component of the baseline evaluation and risk assessment process by which informed decisions are made regarding prostate cancer screening.

Citations: The following articles are submitted in support of this proposed change. We would like to acknowledge the contributions of NCCN panel members who are also co-authors or co-contributors of some of these publications.


Sincerely,

Michael Brawer, MD  
Senior VP Medical Affairs  
Myriad Genetic Laboratories, Inc.

Johnathan Lancaster, MD, PhD  
Chief Medical Officer  
Myriad Genetic Laboratories, Inc.